|
Patent landscape, scope, and claims: |
United States Patent 9,381,179: Claim Scope, Technically Anchored Scope Limits, and Patent Landscape Implications
What does US 9,381,179 claim, in operational terms?
US 9,381,179 claims a skin-treatment method for common acne defined by a specific early clinical effect and a specific formulation strength of adapalene (a retinoid).
Core subject matter (Claim 1)
Claim 1 is a method claim that requires all of the following elements:
- Patient/condition: “common acne afflicting an individual’s skin” where the individual is “in need of such treatment.”
- Dosing regimen: topically administering daily.
- Active concentration: a pharmaceutical composition comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or a salt thereof.
- Dosage form: gel or cream.
- Performance/time-to-effect requirement: “early onset of action occurring by two weeks after treatment begins.”
- Comparative superiority requirement:
- demonstrated by regression of non-inflammatory lesions after two weeks,
- with regression greater than:
- vehicle alone, or
- a “similar composition comprising 0.1% by weight of adapalene” after two weeks.
This is not a generic “treat acne with adapalene” claim. It is a dose-strength + regimen + early-response endpoint + comparative benchmark claim.
What are the claim-by-claim scope boundaries?
How broad is Claim 1?
Claim 1 is broad across two dimensions and narrow across others.
Broad elements
- Dosage form: covers both gel and cream.
- Method framing: directed to a “method for eliciting an early onset of action,” rather than a composition per se.
Narrow elements
- Adapalene strength: fixed at 0.3% by weight (not “about 0.3%,” based on the text you provided).
- Specific outcome window and comparator: requires the response to be demonstrated at two weeks, and requires greater-than effects versus:
- vehicle, and
- a 0.1% adapalene comparator.
Practical implication for infringement analysis
- A product/formulation at 0.3% adapalene used daily can still fall outside if the early-effect criterion at two weeks is not demonstrated to be greater than the comparator(s).
- Conversely, a formulation with other strengths (e.g., 0.15%, 0.2%, or 0.4%) does not meet the active-strength limitation as stated.
What do Claims 2 and 3 add?
- Claim 2: limits the method to acne that is moderate to moderately severe.
- Claim 3: limits composition form and excipient composition, specifying a gel with:
- adapalene,
- carbomer 940,
- disodium edetate,
- methyl paraben,
- poloxamer 124,
- propylene glycol,
- sodium hydroxide,
- purified water.
Scope consequence
- Claim 3 is a dependent narrowing: even if Claim 1 covers gel or cream at 0.3%, Claim 3 locks to a particular gel formulation recipe (at least by listed excipients) and to the Claim 2 disease severity (because it depends on Claim 2).
How do Claims 4, 5, and 6 interact?
- Claim 4: depends on Claim 2 and includes the same detailed gel excipient list as Claim 3.
- Claim 5: depends on Claim 1 and limits dosage form to gel.
- Claim 6: depends on Claim 2 and limits dosage form to gel.
Net effect
- The family of dependent claims distributes coverage across:
- gel-only variants (Claims 5 and 6),
- moderate to moderately severe patients (Claims 2 and 6),
- and a specifically enumerated gel formulation composition (Claims 3 and 4).
What is the effective claim “anchor” that drives infringement and validity risk?
Across the independent claim language you supplied, there is one dominant anchor: early regression of non-inflammatory lesions after two weeks, proven to be greater than vehicle and greater than 0.1% adapalene.
That anchor functions like a functional efficacy limitation. It makes the claimed method depend on:
- the timepoint (two weeks),
- the lesion type (non-inflammatory lesions),
- and the comparative benchmark (vehicle and 0.1%).
Claim construction impact (business lens)
- If an accused product is 0.3% adapalene in gel/cream and is dosed daily, it still may not satisfy Claim 1 unless its two-week non-inflammatory lesion regression is demonstrated to be greater than the stated comparators.
- For at-risk product teams, the infringement question becomes a clinical-data and design-of-study question, not only a formulation chemistry question.
What does this imply for the US patent landscape around adapalene for acne?
Even without additional bibliographic prosecution data in your prompt, this claim set strongly signals how the patent landscape tends to be structured in acne therapeutics:
1) The landscape is typically partitioned by:
- API identity (adapalene itself),
- API dose strength (0.1% vs 0.3%),
- vehicle and formulation type (gel vs cream; excipient system),
- labeling/indication constraints (severity categories),
- efficacy timing and endpoints (early onset within two weeks; non-inflammatory lesion regression),
- comparative performance (superiority vs vehicle and a specific lower-dose comparator).
Your claims specifically blend dose strength with a time-window efficacy and a comparator, which is a common strategy to carve out patentable differentiation even when the active ingredient is known.
2) Likely competitive design-arounds (scope-relevant)
From the limitations you provided, the most direct “escape routes” are:
- Avoid the 0.3% concentration (Claim 1 is tied to 0.3% by weight).
- Use different dosing schedules (daily is stated; alternative schedules may reduce fit).
- Avoid gel/cream mapping if the claim is enforced strictly as written (Claim 1 covers gel or cream; Claim 5/6 are gel-only).
- Target only inflammatory lesions or endpoints instead of “non-inflammatory lesions” regression at two weeks (Claim 1 is tied to non-inflammatory lesion regression).
- Ensure that observed two-week performance is not “greater than” vehicle or the specified 0.1% comparator (this is both a clinical reality and an evidentiary risk).
3) Excipients and gel recipe: narrower but still important
Claims 3 and 4 enumerate a gel formulation excipient package. In freedom-to-operate terms:
- A 0.3% adapalene gel that deviates materially in excipients may still be at risk under Claims 1/2/5/6 (if gel and dose strength and endpoint are met).
- Excipients matter most for narrowing to the specific formulation-dependent claims (Claims 3 and 4), not for eliminating all risk under Claim 1.
How to read the claim language as a “claims map” for litigatable coverage
Decision matrix for scope fit
| Requirement |
Claim 1 |
Claim 2 |
Claim 3/4 |
Claim 5/6 |
| Condition: common acne |
Yes |
Yes |
Yes |
Yes |
| Severity: moderate to moderately severe |
Not required |
Required |
Required (via Claim 2) |
Required (via Claim 2) |
| API: adapalene or salt |
Yes |
Yes |
Yes |
Yes |
| Concentration |
0.3% by weight |
0.3% by weight |
0.3% by weight |
0.3% by weight |
| Formulation type |
gel or cream |
gel or cream |
gel with listed excipients |
gel |
| Dosing |
daily topical |
daily topical |
daily topical |
daily topical |
| Endpoint |
early onset by 2 weeks |
early onset by 2 weeks |
early onset by 2 weeks |
early onset by 2 weeks |
| Lesion type |
regression of non-inflammatory lesions |
same |
same |
same |
| Comparative benchmark |
greater than vehicle and greater than 0.1% adapalene |
same |
same |
same |
This map shows that every dependent claim still inherits the performance and comparator language of Claim 1.
Patent landscape implications for product developers and investors
What this claim set suggests about enforceability strategy
The claims appear crafted to:
- Differentiate a higher-dose adapalene (0.3%) from a lower-dose comparator (0.1%).
- Tie patent coverage to a specific clinical timing (two weeks) and specific lesion type (non-inflammatory).
- Enable multiple coverage routes:
- broad method coverage (Claim 1),
- patient-severity narrowing (Claim 2),
- formulation-excipient narrowing (Claims 3 and 4),
- and gel-only narrowing (Claims 5 and 6).
How R&D teams should interpret “risk”
For a firm developing an acne topical:
- Formulation strength is the first gate: 0.3% adapalene is the central gate in your claim text.
- Clinical evidence timing is the second gate: two-week non-inflammatory lesion regression.
- Comparators are the third gate: vehicle and 0.1% adapalene.
In other words, patent risk for this family is tied to what can be demonstrated in a controlled setting, not just what is formulated.
Key Takeaways
- US 9,381,179 claims a daily topical method for acne that requires 0.3% by weight adapalene and an early endpoint by two weeks: greater regression of non-inflammatory lesions versus vehicle and versus a 0.1% adapalene comparator.
- Dependent claims narrow to moderate to moderately severe acne and, in gel-dependent claims, to a specific excipient set (carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide, purified water).
- The practical enforcement and design-around space is driven by three constraints: dose strength (0.3%), two-week efficacy timing on non-inflammatory lesions, and comparative superiority evidence versus vehicle and 0.1% adapalene.
FAQs
-
Does this patent cover any adapalene topical for acne?
No. The method requires daily topical administration of a composition with 0.3% by weight adapalene and an early effect within two weeks on non-inflammatory lesion regression with specified superiority versus vehicle and 0.1% adapalene.
-
Is gel coverage broader than cream in this patent?
Claim 1 covers gel or cream. Claims 5 and 6 add gel-only narrowing.
-
What is the most litigable limitation in Claim 1?
The functional clinical endpoint: regression of non-inflammatory lesions after two weeks that is greater than vehicle and greater than 0.1% adapalene.
-
Do Claims 3 and 4 require the specific excipient formulation?
Yes. Claims 3 and 4 define a gel with a listed excipient package (carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide, purified water).
-
Can a 0.3% adapalene product still avoid Claim 1?
Yes, if the two-week superiority requirements tied to non-inflammatory lesion regression versus vehicle and 0.1% adapalene are not met under the claimed method conditions.
References
- User-provided claim text for US Drug Patent 9,381,179 (Claims 1-6).
More… ↓
⤷ Start Trial
|
